Search research articles
Contact Us
Filters
Showing results (71-80 of 83) with videos related to
Page
of 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
M D Galsky, J E Gschwend, M I Milowsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2018
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y-J Bang, E Yañez Ruiz, E Van Cutsem, et al.
Prostate Cancer and Prostatic Diseases
|
January 13, 2016
In vivo prostate cancer detection and grading using restriction spectrum imaging-MRI
K C McCammack, C J Kane, J K Parsons, et al.
Genome Medicine
|
January 12, 2020
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data
Ilan Shomorony, Elizabeth T Cirulli, Lei Huang, et al.
Abdominal Radiology (New York)
|
February 25, 2016
Restriction spectrum imaging improves MRI-based prostate cancer detection
Kevin C McCammack, Natalie M Schenker-Ahmed, Nathan S White, et al.
Frontiers in Oncology
|
March 6, 2015
MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens
Michael A Liss, Nathan S White, J Kellogg Parsons, et al.
ESMO Open
|
May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
D P Carbone, T-E Ciuleanu, M Cobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2026
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649
Y Y Janjigian, K Shitara, J A Ajani, et al.
ESMO Open
|
December 5, 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]
M Reck, T-E Ciuleanu, M Cobo, et al.
ESMO Open
|
October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
M Reck, T-E Ciuleanu, M Cobo, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 83) with videos related to
Sort By:
Page
of 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
M D Galsky, J E Gschwend, M I Milowsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2018
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y-J Bang, E Yañez Ruiz, E Van Cutsem, et al.
Prostate Cancer and Prostatic Diseases
|
January 13, 2016
In vivo prostate cancer detection and grading using restriction spectrum imaging-MRI
K C McCammack, C J Kane, J K Parsons, et al.
Genome Medicine
|
January 12, 2020
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data
Ilan Shomorony, Elizabeth T Cirulli, Lei Huang, et al.
Abdominal Radiology (New York)
|
February 25, 2016
Restriction spectrum imaging improves MRI-based prostate cancer detection
Kevin C McCammack, Natalie M Schenker-Ahmed, Nathan S White, et al.
Frontiers in Oncology
|
March 6, 2015
MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens
Michael A Liss, Nathan S White, J Kellogg Parsons, et al.
ESMO Open
|
May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
D P Carbone, T-E Ciuleanu, M Cobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2026
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649
Y Y Janjigian, K Shitara, J A Ajani, et al.
ESMO Open
|
December 5, 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]
M Reck, T-E Ciuleanu, M Cobo, et al.
ESMO Open
|
October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
M Reck, T-E Ciuleanu, M Cobo, et al.
Page
of 9